GlassScriptPhysician profile
Christopher David Shawl
NPI 1528394574
$811.03
in general payments reported to CMS, 2019-2025
15 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.60 · 2022: $152 · 2024: $152 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $217.67 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $104.51 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $86.08 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.96 | 2025 | Caplyta |
| Novo Nordisk INC | $57.65 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Indivior INC. | $43.97 | 2025 | Sublocade |
| Seqirus USA INC | $40.44 | 2025 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $36.08 | 2022-2025 | Spravato |
| Dexcom, INC. | $34.36 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $31.18 | 2025 | Rotarix, Bexsero, Pediarix |
| Astrazeneca Pharmaceuticals LP | $21.64 | 2025 | Farxiga |
| Gilead Sciences, INC. | $19.23 | 2024 | |
| Recor Medical INC | $16.95 | 2024 | Paradise Renal Denervation System |
| Otsuka America Pharmaceutical, INC. | $15.12 | 2021 | |
| Exact Sciences Corporation | $14.19 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Shawl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.